Platinum-Resistant Relapsed Ovarian Cancer Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Key Companies - Aravive, Alkermes, Corcept Therapeutics, Immunovaccine, Mersana Therapeutics, ImmunoGen

In 2021, the Platinum-Resistant Relapsed Ovarian Cancer Market size in the 7MM was estimated to be around USD 1,500 million, which is expected to rise with a significant CAGR during the study period (2019-2032). As per DelveInsight, the Platinum-Resistant Relapsed Ovarian Cancer Market is anticipated to evolve immensely in the coming years owing to the already prescribed products along with the launch of emerging therapies and the rise in the number of cases of ovarian cancer in the 7MM.

DelveInsight's "Platinum-Resistant Relapsed Ovarian Cancer Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Platinum-Resistant Relapsed Ovarian Cancer Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Platinum-Resistant Relapsed Ovarian Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Platinum-Resistant Relapsed Ovarian Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Platinum-Resistant Relapsed Ovarian Cancer: An Overview
Ovarian cancer is a disease that affects women and is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

Platinum-based chemotherapy (usually in combination with surgery) is the mainstay first-line drug treatment for ovarian cancer tumors. At the time of diagnosis, most patients have advanced-stage disease and despite debulking surgery and platinum-based chemotherapy, the majority will experience disease recurrence requiring further treatment. The most widely used predictor of the likelihood of response to subsequent platinum-based chemotherapy has been the platinum-free interval. Patients with recurrent ovarian cancer are typically categorized as having either platinum-resistant or platinum-sensitive disease, based on a platinum-free interval of less than or greater than 6 months, but some studies use progression-free interval (PFI) to define Platinum-resistant ovarian cancer. This primary platinum resistance is mainly observed in non-high-grade serous ovarian carcinoma (HGSOC) subtypes such as clear cell, mucinous, and low-grade serous carcinoma.

Platinum-Resistant Relapsed Ovarian Cancer Market Key Facts
• In the year 2021, approximately 61,000 ovarian cancer cases were diagnosed in the 7MM.
• Among the 7MM countries, the highest number of incident cases of ovarian cancer were observed in the US, which accounted for around 21,000 cases in the year 2021.
• In the US, approximately 11,000 cases progressed to the next line of therapy after taking first-line therapy in the year 2021. Moreover, overall, the total treated pool of patients progressing to the further line of therapies after receiving the first line of therapy in the year 2021 was observed to be around 23,000 cases in the US.
• As per Leung and Konstantinopoulos (2021), for platinum-resistant recurrent ovarian cancer (PROC), the documented response rates are poor (15% to 20%) for most chemotherapy agents, which remain the mainstay of treatment
• According to the Surveillance, Epidemiology, and End Results (SEER) Program, the rate of new cases of ovarian cancer was 10.6 per 100,000 women per year. The death rate was 6.5 per 100,000 women per year. These rates are age-adjusted and based on 2013-2017 cases and 2015-2019 deaths.

Discover How Platinum-Resistant Relapsed Ovarian Cancer Market Will Grow by 2032:
https://www.delveinsight.com/report-store/platinum-resistant-relapsed-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Platinum-Resistant Relapsed Ovarian Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Platinum-Resistant Relapsed Ovarian Cancer therapies in the market. It also provides a detailed assessment of the Platinum-Resistant Relapsed Ovarian Cancer market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Platinum-Resistant Relapsed Ovarian Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Platinum-Resistant Relapsed Ovarian Cancer Epidemiology
The epidemiology section covers detailed insights into the historical, and current Platinum-Resistant Relapsed Ovarian Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Platinum-Resistant Relapsed Ovarian Cancer Epidemiology Segmented as -
• Total Platinum-resistant Ovarian Cancer Cases in the 7MM [2019-2032]
• Total Incident Cases of Ovarian Cancer in the 7MM [2019-2032]
• Total First-line Treated Cases of Ovarian Cancer in the 7MM [2019-2032]
• Total Treated Cases of Platinum-resistant Ovarian Cancer in the 7MM [2019-2032]

Get Key Insights Into the Evolving Platinum-Resistant Relapsed Ovarian Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/platinum-resistant-relapsed-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Platinum-Resistant Relapsed Ovarian Cancer Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Platinum-Resistant Relapsed Ovarian Cancer market or expected to be launched during the study period. The analysis covers the market share by Platinum-Resistant Relapsed Ovarian Cancer drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Platinum-Resistant Relapsed Ovarian Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/platinum-resistant-relapsed-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Platinum-Resistant Relapsed Ovarian Cancer Therapeutics Assessment
The emerging drugs for Platinum-resistant ovarian cancer shall impact the market size significantly, considering the pipeline with a variety of therapeutic classes in the periphery. At present, there is a decent number o biologics and drugs under investigation for the treatment of Platinum-resistant ovarian cancer. Key players such as Immunogen, Aravive Biologics, Mersana Therapeutics, Alkermes, among others going to boost the market dynamics in the coming years with the launch of their pipeline therapies.

Leading Companies in the Platinum-Resistant Relapsed Ovarian Cancer Therapeutics Market Include
• Aravive
• Alkermes
• Corcept Therapeutics
• Immunovaccine
• Mersana Therapeutics
• ImmunoGen
And Many Others

Emerging and Marketed Platinum-Resistant Relapsed Ovarian Cancer Therapies Covered in the Report Include
• Batiraxcept/AVB-S6-500: Aravive
• Nemvaleukin alfa (nemvaleukin, ALKS 4230): Alkermes
• Relacorilant: Corcept Therapeutics
• DPX-Survivac (formerly known as Maveropepimut-S): Immunovaccine
• Upifitamab Rilsodotin (XMT-1536): Mersana Therapeutics
And Many More

Learn More About the Emerging Therapies & Key Companies in the Platinum-Resistant Relapsed Ovarian Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/platinum-resistant-relapsed-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Platinum-Resistant Relapsed Ovarian Cancer Competitive Intelligence Analysis
4. Platinum-Resistant Relapsed Ovarian Cancer Market Overview at a Glance
5. Platinum-Resistant Relapsed Ovarian Cancer Background and Overview
6. Platinum-Resistant Relapsed Ovarian Cancer Patient Journey
7. Platinum-Resistant Relapsed Ovarian Cancer Epidemiology and Patient Population
8. Platinum-Resistant Relapsed Ovarian Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Platinum-Resistant Relapsed Ovarian Cancer Unmet Needs
10. Key Endpoints of Platinum-Resistant Relapsed Ovarian Cancer Treatment
11. Platinum-Resistant Relapsed Ovarian Cancer Marketed Products
12. Platinum-Resistant Relapsed Ovarian Cancer Emerging Therapies
13. Platinum-Resistant Relapsed Ovarian Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Platinum-Resistant Relapsed Ovarian Cancer Market Outlook (7 major markets)
16. Platinum-Resistant Relapsed Ovarian Cancer Access and Reimbursement Overview
17. KOL Views on the Platinum-Resistant Relapsed Ovarian Cancer Market.
18. Platinum-Resistant Relapsed Ovarian Cancer Market Drivers
19. Platinum-Resistant Relapsed Ovarian Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/platinum-resistant-relapsed-ovarian-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Factor XA Inhibitor Market
https://www.delveinsight.com/report-store/factor-xa-inhibitor-market

Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market

Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market

Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market

Thalassemia Market
https://www.delveinsight.com/report-store/thalassemia-market

Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

Chronic Periodontitis Market
https://www.delveinsight.com/report-store/chronic-periodontitis-market

Cryptococcosis Market
https://www.delveinsight.com/report-store/cryptococcosis-market

Exocrine Pancreatic Insufficiency Market
https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-market

Papilloma MarketRespiratory Distress Syndrome Market
https://www.delveinsight.com/report-store/respiratory-distress-syndrome-market

Sinusitis Market
https://www.delveinsight.com/report-store/sinusitis-market

Childhood Atropine For Myopia Progression Market
https://www.delveinsight.com/report-store/childhood-atropine-for-myopia-progression-market

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market

Adeno-Associated Virus Vectors in Gene Therapy Market
https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight
https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight

Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market

Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

Eczema Market
https://www.delveinsight.com/report-store/eczema-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Hemostats Market
https://www.delveinsight.com/report-store/hemostats-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Peripheral Vascular Devices Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market

Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Hemostasis Market
https://www.delveinsight.com/report-store/hemostasis-market

Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market

Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.